SCHEMBL22274

SCHEMBL22274

COc1cccc(OBOc2cccc(OC)c2)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACHE P22303 1/20 0.54
CYP3A4 P08684 2/20 0.52
ALDH1A1 P00352 2/20 0.52
CA1 P00915 1/20 0.52
CA2 P00918 1/20 0.52
CA7 P43166 1/20 0.52
CA9 Q16790 1/20 0.52
SMN1; SMN2 Q16637 1/20 0.48
MAOB P27338 2/20 0.47
CES2 O00748 1/20 0.47
CES1 P23141 1/20 0.47
ENPP2 Q13822 1/20 0.47
CYP1A1 P04798 1/20 0.46
CYP1A2 P05177 1/20 0.46
CYP2E1 P05181 1/20 0.46
CYP2C8 P10632 1/20 0.46
CYP2D6 P10635 1/20 0.46
CYP2A6 P11509 1/20 0.46
CYP2C9 P11712 1/20 0.46
CYP4B1 P13584 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30238353 1.00 ACHE (0.54) ACHECYP3A4ALDH1A1CA1CA2
1,3-Dimethoxybenzene SCHEMBL9350 0.84 ACHE (0.70) ACHECYP3A4ALDH1A1CA1CA2
1,3-Dimethoxybenzene SCHEMBL901285 0.84 ACHE (0.70) ACHECYP3A4ALDH1A1CA1CA2
SCHEMBL22875 0.82 MAOB (0.68) ACHEMAOBIDO1AGXTNPC1
SCHEMBL2604701 0.82 ACHE (0.50) ACHECYP3A4ALDH1A1CA1CA2
1,3-Dimethoxybenzene SCHEMBL28343465 0.82 ACHE (0.67) ACHECYP3A4ALDH1A1CA1CA2
1,3-Dimethoxybenzene SCHEMBL28542304 0.82 ACHE (0.67) ACHECYP3A4ALDH1A1CA1CA2
1,3-Dimethoxybenzene SCHEMBL7860661 0.82 ACHE (0.67) ACHECYP3A4ALDH1A1CA1CA2
1,3-Dimethoxybenzene SCHEMBL15870025 0.82 ACHE (0.67) ACHECYP3A4ALDH1A1CA1CA2
1,3-Dimethoxybenzene SCHEMBL28135915 0.82 ACHE (0.67) ACHECYP3A4ALDH1A1CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 992 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3149138-A1 WATER CLUSTER-DOMINANT BORONIC ACID ALKALI SURFACTANT COMPOSITIONS AND THEIR USE The Procter & Gamble Company (US) 2017-04-05 EP claimed
WO-2015184209-A1 WATER CLUSTER-DOMINANT BORONIC ACID ALKALI SURFACTANT COMPOSITIONS AND THEIR USE THE PROCTER & GAMBLE COMPANY (US) 2015-12-03 WO claimed
US-20150344817-A1 WATER CLUSTER-DOMINANT BORONIC ACID ALKALI SURFACTANT COMPOSITIONS AND THEIR USE THE PROCTER & GAMBLE COMPANY 2015-12-03 US claimed
US-20260132123-A1 ABAD INHIBITOR COMPOUNDS UNIV COURT OF THE UNIV OF ST ANDREWS (GB) 2026-05-14 US disclosed
CN-122029157-A Bilobalide derivatives for the treatment of neurological diseases and cancers 香港中文大学 2026-05-12 CN disclosed
US-20260078117-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS INC (US) 2026-03-19 US disclosed
US-20260034127-A1 TREATMENT OF GVHD KADMON CORP LLC (FR) 2026-02-05 US disclosed
US-20260035398-A1 TETRADENTATE AND OCTAHEDRAL METAL COMPLEXES CONTAINING NAPHTHYRIDINOCARBAZOLE AND ITS ANALOGUES UNIV ARIZONA STATE (US) 2026-02-05 US disclosed
US-20250388582-A1 NOVEL BICYCLIC HETEROARYL COMPOUND AND USE THEREOF ILDONG PHARMACEUTICAL CO LTD (KR) 2025-12-25 US disclosed
US-20250304565-A1 NOVEL BENZOFURAN, BENZOTHIOPHENE, AND INDOLE ANALOGS THAT INHIBIT THE FORMATION OF TAU OLIGOMERS AND THEIR METHOD OF USE Oligomerix Inc. (US) 2025-10-02 US disclosed
US-20250296938-A1 Compounds that Interact with the Ras Superfamily for the Treatment of Cancers, Inflammatory Diseases, Rasopathies, and Fibrotic Disease SHY Therapeutics LLC (US) 2025-09-25 US disclosed
EP-0873123-A4 INHIBITORS OF PROTEIN ISOPRENYL TRANSFERASES UNIV PITTSBURGH (US) 1999-02-03 EP disclosed
EP-0888317-A1 SUBSTITUTED 4-HYDROXY-PHENYLALCANOIC ACID DERIVATIVES WITH AGONIST ACTIVITY TO PPAR-GAMMA GLAXO GROUP LIMITED (GB) 1999-01-07 EP disclosed
EP-0873123-A1 INHIBITORS OF PROTEIN ISOPRENYL TRANSFERASES UNIVERSITY OF PITTSBURGH (US) 1998-10-28 EP disclosed
WO-1998037068-A1 BENZOIC ACID DERIVATIVES AND RELATED COMPOUNDS AS ANTIARRHYTHMIC AGENTS BRISTOL-MYERS SQUIBB COMPANY (US) 1998-08-27 WO disclosed
EP-0811001-A1 BENZOTHIAZINE DIOXIDES AS ENDOTHELIN ANTAGONISTS WARNER-LAMBERT COMPANY (US) 1997-12-10 EP disclosed
WO-1997031907-A1 SUBSTITUTED 4-HYDROXY-PHENYLALCANOIC ACID DERIVATIVES WITH AGONIST ACTIVITY TO PPAR-GAMMA GLAXO GROUP LIMITED (GB) 1997-09-04 WO disclosed
WO-1997017070-A1 INHIBITORS OF PROTEIN ISOPRENYL TRANSFERASES UNIVERSITY OF PITTSBURGH (US) 1997-05-15 WO disclosed
US-5599811-A PHENYL OR DIOXYPHENYL SUBSTITUENTS; DRUGS WARNER-LAMBERT COMPANY (US) 1997-02-04 US disclosed
WO-1996026195-A1 BENZOTHIAZINE DIOXIDES AS ENDOTHELIN ANTAGONISTS WARNER-LAMBERT COMPANY (US) 1996-08-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260035398-A1 TETRADENTATE AND OCTAHEDRAL METAL COMPLEXES CONTAINING NAPHTHYRIDINOCARBAZOLE AND ITS ANALOGUES LBR, SCO2, RAD54L ACHE 4728/4885CYP3A4 1196/4885ALDH1A1 2242/4885
US-20260034127-A1 TREATMENT OF GVHD ROCK2, RHOA, MYH2 ACHE 4450/4885CYP3A4 3141/4885ALDH1A1 3146/4885
US-20260132123-A1 ABAD INHIBITOR COMPOUNDS ADH1C, ADH1A, CBR1 ACHE 591/4885CYP3A4 1138/4885ALDH1A1 52/4885
US-20250304565-A1 NOVEL BENZOFURAN, BENZOTHIOPHENE, AND INDOLE ANALOGS THAT INHIBIT THE FORMATION OF TAU OLIGOMERS AND THEIR METHOD OF USE MAPT, HTT, APP ACHE 255/4885CYP3A4 986/4885ALDH1A1 1687/4885
US-20250388582-A1 NOVEL BICYCLIC HETEROARYL COMPOUND AND USE THEREOF GBA1, PIKFYVE, MAN2B1 ACHE 4528/4885CYP3A4 4110/4885ALDH1A1 3837/4885
US-20250296938-A1 Compounds that Interact with the Ras Superfamily for the Treatment of Cancers, Inflammatory Diseases, Rasopathies, and Fibrotic Disease HRAS, KRAS, NRAS ACHE 4849/4885CYP3A4 4830/4885ALDH1A1 3359/4885
US-20260078117-A1 COMPOUNDS AND METHODS OF USE NR3C2, ADRA1A, CNR1 ACHE 2392/4885CYP3A4 706/4885ALDH1A1 100/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.